Efficacy and safety of Amomum villosum extracts in obese adults: A randomized, double-blind, placebo-controlled trial

Abstract

ObjectiveThis study aimed to assess how well Amomum villosum water extract (AVE) assisted overweight to moderately obese people in losing weight. MethodsEighty participants were chosen at random for the AVE group or the placebo group for this experiment. Subjects were given two tablets of the test substance after their two consistent meals daily for 12 weeks. At the starting and completion of the experiment, measurements of body mass index (BMI), body weight, percent body fat, body fat mass, visceral adipose tissue (VAT), lean body mass, subcutaneous adipose tissue (SAT), percent VAT (%), and percent SAT (%) were taken. Before and after the study, blood samples were obtained for safety laboratory parameters. ResultsAfter taking the products for 12 weeks, the AVE group lost considerably more weight than the placebo group (-2.04 ± 3.04 kg vs −0.30 ± 2.88 kg, respectively; P < 0.014). Additionally, the AVE group showedreduction in body fat mass of −1393.63 ± 2268.80 g as compared to the placebo group's reduction of 51.67 ± 2111.05 g (P < 0.006). In comparison to the placebo group, VAT and SAT weight significantly lowered in the AVE group. There were no negative effects associated with AVE consumption. Before and after AVE administration, 31 of 38 participants (81.6 %) lost weight. Similarly, 26 of 38 members (68.4 %) lost weight and body fat mass before and after AVE administration. ConclusionsThese results suggest that AVE might be a reliable and secure weight regulation. WKUIOMH-IRB-2020–01 is the registration number for this trial.